MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
August 02, 2021 16:05 ET
|
MediWound Ltd.
YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
July 28, 2021 07:00 ET
|
MediWound Ltd.
Independent Data Monitoring Committee Recommends Continuation of the Study withNo Changes to Study Sample Size No Safety Concerns Identified Full Study Enrollment Expected by Year-End 2021;...
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
July 26, 2021 07:00 ET
|
MediWound Ltd.
Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a...
MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
July 20, 2021 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair...
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
July 09, 2021 08:00 ET
|
MediWound Ltd.
Study Findings Demonstrate Strong Results in Debriding Venous Leg Ulcers and Diabetic Foot Ulcers Interim Assessment of Ongoing U.S. Phase II Adaptive Design Study in Venus Leg Ulcers Expected End of...
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
June 29, 2021 08:45 ET
|
MediWound Ltd.
YAVNE, Israel, June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair...
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
June 09, 2021 16:30 ET
|
MediWound Ltd.
YAVNE, Israel, June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
June 07, 2021 07:00 ET
|
MediWound Ltd.
Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 ...
MediWound Reports First Quarter 2021 Financial Results
May 05, 2021 07:00 ET
|
MediWound Ltd.
First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year Conference call begins today at 8:30 am ET YAVNE, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD),...
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
April 26, 2021 16:20 ET
|
MediWound Ltd.
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...